A new generic abortion pill hits the market, IVF access expands, and home births surge—each framed as progress, each carrying hidden costs. We pull apart the headlines and ask the harder question: what protects vulnerable lives when policy moves faster than moral clarity? First, we unpack the FDA’s approval of another mifepristone generic and why “identical formulation” doesn’t settle the ethical debate. Safety talk often skims maternal side effects while ignoring the unborn child’s near‑cer...
All content for The Life Challenges Podcast is the property of Christian Life Resources and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
A new generic abortion pill hits the market, IVF access expands, and home births surge—each framed as progress, each carrying hidden costs. We pull apart the headlines and ask the harder question: what protects vulnerable lives when policy moves faster than moral clarity? First, we unpack the FDA’s approval of another mifepristone generic and why “identical formulation” doesn’t settle the ethical debate. Safety talk often skims maternal side effects while ignoring the unborn child’s near‑cer...
David & Bathsheba: The Cost of Hidden Sin with Professor Emeritus Mark Braun
The Life Challenges Podcast
37 minutes
3 months ago
David & Bathsheba: The Cost of Hidden Sin with Professor Emeritus Mark Braun
Special guest Professor Emeritus Mark Braun joins us to unpack the familiar biblical narrative of David and Bathsheba through a more nuanced lens. The story reveals deeper complexities than typically discussed, showing how a powerful king compartmentalized his life while covering up serious sin until confronted by Nathan the prophet. This episode offers profound insight for anyone struggling with hidden sin or its aftermath. While forgiveness is complete and unconditional, consequences often...
The Life Challenges Podcast
A new generic abortion pill hits the market, IVF access expands, and home births surge—each framed as progress, each carrying hidden costs. We pull apart the headlines and ask the harder question: what protects vulnerable lives when policy moves faster than moral clarity? First, we unpack the FDA’s approval of another mifepristone generic and why “identical formulation” doesn’t settle the ethical debate. Safety talk often skims maternal side effects while ignoring the unborn child’s near‑cer...
